144 related articles for article (PubMed ID: 8024805)
1. Comparison of the effects of calcipotriol, prednicarbate and clobetasol 17-propionate on normal skin assessed by ultrasound measurement of skin thickness.
Lévy J; Gassmüller J; Schröder G; Audring H; Sönnichsen N
Skin Pharmacol; 1994; 7(4):231-6. PubMed ID: 8024805
[TBL] [Abstract][Full Text] [Related]
2. 0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream.
Korting HC; Vieluf D; Kerscher M
Eur J Clin Pharmacol; 1992; 42(2):159-61. PubMed ID: 1618247
[TBL] [Abstract][Full Text] [Related]
3. Effects of calcipotriol and clobetasol-17-propionate on UVB-irradiated human skin: an immunohistochemical study.
van der Vleuten CJ; Snijders CG; de Jong EM; van de Kerkhof PC
Skin Pharmacol; 1996; 9(6):355-65. PubMed ID: 9055356
[TBL] [Abstract][Full Text] [Related]
4. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis.
Austad J; Bjerke JR; Gjertsen BT; Helland S; Livden JK; Morken T; Mørk NJ
J Eur Acad Dermatol Venereol; 1998 Jul; 11(1):19-24. PubMed ID: 9731961
[TBL] [Abstract][Full Text] [Related]
5. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream.
Rigopoulos D; Ioannides D; Prastitis N; Katsambas A
Acta Derm Venereol; 2002; 82(2):140. PubMed ID: 12125946
[No Abstract] [Full Text] [Related]
6. Local tolerability of topically applied methylprednisolone aceponate.
Kecskés A; Jahn P; Lange L
J Am Acad Dermatol; 1993 May; 28(5 Pt 1):786-8. PubMed ID: 8496430
[No Abstract] [Full Text] [Related]
7. Different skin thinning potential of equipotent medium-strength glucocorticoids.
Korting HC; Unholzer A; Schäfer-Korting M; Tausch I; Gassmueller J; Nietsch KH
Skin Pharmacol Appl Skin Physiol; 2002; 15(2):85-91. PubMed ID: 11867964
[TBL] [Abstract][Full Text] [Related]
8. Topical hydrocortisone, clobetasol propionate, and calcipotriol do not increase photocarcinogenesis induced by simulated solar irradiation in hairless mice.
Lerche CM; Philipsen PA; Poulsen T; Wulf HC
Exp Dermatol; 2010 Nov; 19(11):973-9. PubMed ID: 20113348
[TBL] [Abstract][Full Text] [Related]
9. Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound.
Kerscher MJ; Korting HC
Acta Derm Venereol; 1992; 72(3):214-6. PubMed ID: 1357864
[TBL] [Abstract][Full Text] [Related]
10. 0.05% clobetasol 17-propionate cream and ointment but not the corresponding 0.1% triamcinolone acetonide preparations increase skin surface roughness: a possible dissociation of unwanted epidermal and dermal effects.
Kerscher MJ; Korting HC; Mehringer L; Mätzig R
Skin Pharmacol; 1996; 9(2):120-3. PubMed ID: 8722606
[TBL] [Abstract][Full Text] [Related]
11. Topical glucocorticoids and thinning of normal skin as to be assessed by ultrasound.
Korting HC
Curr Probl Dermatol; 1993; 21():114-21. PubMed ID: 8299364
[No Abstract] [Full Text] [Related]
12. Calcipotriol ointment versus clobetasol ointment in localized vitiligo: an open, comparative clinical trial.
Köse O; Riza Gür A; Kurumlu Z; Erol E
Int J Dermatol; 2002 Sep; 41(9):616-8. PubMed ID: 12358838
[No Abstract] [Full Text] [Related]
13. A comparison of the effects of topical treatment of calcipotriol, camptothecin, clobetasol and tazarotene on an imiquimod-induced psoriasis-like mouse model.
Sun J; Dou W; Zhao Y; Hu J
Immunopharmacol Immunotoxicol; 2014 Feb; 36(1):17-24. PubMed ID: 24286371
[TBL] [Abstract][Full Text] [Related]
14. Combination of calcipotriol and clobetasol propionate as a premixed ointment for the treatment of psoriasis.
Katoh N; Kishimoto S
Eur J Dermatol; 2003; 13(4):382-4. PubMed ID: 12948920
[TBL] [Abstract][Full Text] [Related]
15. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis.
Reygagne P; Mrowietz U; Decroix J; de Waard-van der Spek FB; Acebes LO; Figueiredo A; Caputo R; Poncet M; Arsonnaud S
J Dermatolog Treat; 2005 Feb; 16(1):31-6. PubMed ID: 15897165
[TBL] [Abstract][Full Text] [Related]
16. Comparative atrophogenicity potential of medium and highly potent topical glucocorticoids in cream and ointment according to ultrasound analysis.
Kerscher MJ; Korting HC
Skin Pharmacol; 1992; 5(2):77-80. PubMed ID: 1637562
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive evaluation of topical calcipotriol versus clobetasol in the treatment of psoriasis.
Berardesca E; Vignoli GP; Farinelli N; Vignini M; Distante F; Rabbiosi G
Acta Derm Venereol; 1994 Jul; 74(4):302-4. PubMed ID: 7976093
[TBL] [Abstract][Full Text] [Related]
18. Nanoemulsion loaded gel for topical co-delivery of clobitasol propionate and calcipotriol in psoriasis.
Kaur A; Katiyar SS; Kushwah V; Jain S
Nanomedicine; 2017 May; 13(4):1473-1482. PubMed ID: 28259803
[TBL] [Abstract][Full Text] [Related]
19. Topical application of calcipotriene and corticosteroids: combination regimens.
Lebwohl M
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 2):S55-8. PubMed ID: 9344186
[TBL] [Abstract][Full Text] [Related]
20. Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo.
Serup J; Holm P
Dermatologica; 1985; 170(4):189-94. PubMed ID: 3888708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
